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Abstract
Primary involvement of skeletal muscle is a very rare event in ALK-1 positive anaplastic large cell lymphoma (ALCL).
We describe a case of a 10-year old boy presenting with a three week history of pain and a palpable firm swelling
at the dorsal aspect of the left thigh. Histological examination of the lesion revealed a tumoral and diffuse
polymorphic infiltration of the muscle by large lymphoid cells. Tumor cells displayed eccentric, lobulated “horse
shoe” or “kidney-shape” nuclei. The cells showed immunohistochemical positivity for CD30, ALK-1, CD2, CD3, CD7,
CD8, and Perforin. Fluorescence in situ hybridization analysis revealed a characteristic rearrangement of the ALK-1
gene in 2p23 leading to the diagnosis of ALK-1 positive ALCL. Chemotherapy according to the ALCL-99-NHL-BFM
protocol was initiated and resulted in a complete remission after two cycles. This case illustrates the unusual
presentation of a pediatric ALCL in soft tissue with a good response to chemotherapy.
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Background
Anaplastic large cell lymphoma (ALCL) was discovered by
Stein et al. and characterized by strong expression of the
Ki-1 (CD30) antigen [1]. In 1988, ALCL was included in
the revised Kiel classification and is nowadays classified as
a Non-Hodgkin lymphoma of T-cell origin by the World
Health Organization [2,3]. The key moment in under-
standing the primary biological driver behind ALCL was
the discovery of the recurrent t(2;5)(p23;q35) translocation
in this lymphoma type [4]. This finding was further eluci-
dated by Morris and colleagues who identified the two
genes involved in this translocation: the anaplastic lym-
phoma kinase (ALK-1) on chromosome 2 and nucleo-
phosmin (NPM1) on chromosome 5 [5]. Subsequently, the
NPM-ALK fusion protein was proven to have oncogenic
capacity [6]. Among the four main types of pediatric non-
Hodgkin lymphoma (Burkitt lymphoma, diffuse large B-
cell lymphoma, anaplastic large cell lymphoma and lym-
phoblastic lymphoma) ALCL has the best prognosis:
event-free and overall survival rates were 72% and 88%,
respectively, even in advanced-stage diseases [7].
Here, we report a case of a 10-year old boy diagnosed
with an ALK-1 positive anaplastic large cell lymphoma of
the skeletal muscle. Primary involvement of skeletal mus-
cle by ALCL is extremely rare and so far only four pedia-
tric cases have been reported in the literature [8-11].
Case presentation
Initial presentation and management
A 10-year old boy presented with a painful swelling in
the dorsal aspect of the left distal thigh without history of
trauma. Pain started 3 weeks before, increased with time
and resulted in difficulties in walking at time of presenta-
tion. No fever, night sweats or weight loss was reported.
Physical examination revealed a 9 × 4 cm palpable firm
mass in the biceps femoris muscle. Magnetic resonance
imaging (MRI) demonstrated a 4 × 3 × 9 cm ill-defining
tumor within the long head of the biceps femoris muscle
with vivid uptake of contrast medium (Figure 1). Also,
enlarged lymph nodes up to a diameter of 2 cm were
detected popliteal, inguinal and iliac. Radiologically, the
most probable diagnosis was a malignant soft tissue
* Correspondence: timo_gaiser@web.de
1Institute of Pathology, Medical Faculty Mannheim, University of Heidelberg,
Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
Full list of author information is available at the end of the article
Gaiser et al. Diagnostic Pathology 2012, 7:38
http://www.diagnosticpathology.org/content/7/1/38
© 2012 Gaiser et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.tumor, most likely a rhabdomyosarcoma. Beside slightly
enlarged inguinal and popliteal lymph nodes further sta-
ging did not reveal other organ or skin involvement.
Laboratory HIV 1 + 2 screening tests showed no signs
for HIV infection. Histological diagnosis was achieved by
incisional biopsy. After being classified as Murphy stage
II [12], further treatment was conducted according to the
international protocol for childhood ALCL (ALCL-99-
NHL-BFM). ALK-1/NPM PCR was found positive in per-
ipheral blood. After two cycles of chemotherapy the
tumor was no longer detectable clinically or by ultra-
sound. The patient is currently receiving further che-
motherapy without experiencing major toxicity.
Materials and methods
Immunohistochemistry
Four micron tissue sections were stained with the following
monoclonal antibodies: CD2, CD7, CD20, CD30, CD31,
CD79, CD99, CD117, Alk-1, Desmin, D2-40, EMA, Ki67,
TdT (all Dako Cytomation, Glostrup; Denmark), CD3, bF1
(T-cell receptor beta chains) (both Thermo Fisher Scienti-
fic, Waltham, MA, USA), CD5, CD8, CD10, CD56, Perforin
(Leica, Wetzlar, Germany), and CD34 (Immunotech, Glen-
dale, CA, USA). Antibody binding was visualized using the
Envision System as described by the manufacturer.
In situ hybridization
In situ hybridization analyses for the t(2;5) translocation
and for Epstein-Barr virus (EBV) encoded small nuclear
RNAs (EBERs) was performed on four micron sections
of formalin fixed, paraffin-embedded tissue paraffin sec-
tions using the ALK Dual Color, Break Apart Rearrange-
ment Probe (Abbott, North Chicago, IL, USA) and
ZytoFast™ EBV Probe (ZytoVision GmbH, Bremerha-
ven, Germany); procedures were performed according to
the manufacturers’ indications.
Results
Histologically, the muscle of the biceps femoris displayed a
diffuse polymorphic lymphoid infiltration of high mitotic
activity, including atypical mitoses. While no haemangio
invasion was demonstrable, lymphovascular invasion was
detectable morphologically and by D2-40 immunohisto-
chemistry. The majority of tumor cells was small to mid-
dle sized with pleomorphic nuclei and variable amount of
pale cytoplasm. Intermingled and less common were lar-
ger cells with eccentric lobulated “horse shoe” or “kidney-
shape” nuclei and abundant cytoplasm with an intense
eosinophilic region representing the Golgi apparatus (Fig-
ure 2A). These “hallmark cells” strongly expressed CD30,
while the smaller lymphoid cells were only moderately
positive (Figure 2B). Furthermore, the tumor cells stained
positive for CD2, CD3, CD7 (Figure 2C), CD99, Perforin
and, remarkably, CD8 (Figure 2D). ALK-1 had an obvious
cytoplasmic and nuclear pattern of immunoreactivity in
the tumor cells (Figure 2E). As expected, rearrangement of
the ALK-1 gene in 2p23 could be proven by fluorescence
in situ hybridization analyses (Figure 2F). The whole
tumor cell population revealed a CD5 antigen loss and a
weak and obviously only cytoplasmic reactivity for bF1.
The Ki67 proliferation index reached ~60%. Tumor cells
stained negative for CD10, CD20, CD79a, CD34, CD56,
CD117, TdT, Desmin, and EMA. With EBER in situ hybri-
dization no EBV positive cells were detectable. Based on
these findings the diagnosis of CD30/ALK-1 positive ana-
plastic large cell lymphoma was established and confirmed
by the reference center for lymphoid malignancies in
Würzburg (AR, EG).
Conclusions
ALCL can be classified into ALK-1 negative and ALK-1
positive ALCL. ALK-1 negative ALCL occurs mainly in
older patients (peak incidence ~ 60 y) and in advanced-
stage disease. ALK-1 positive ALCL is a clinically aggres-
sive lymphoma that mostly occurs in the first three
decades of life [13]. However, overall survival and longer
disease free survival is observed after treatment with
aggressive chemotherapy. Patients affected by ALK-1 posi-
tive ALCL have a significant better overall survival than
ALK-1 negative ALCL patients (5-year overall survival: 70-
80% vs. 33-49%) [14,15]. It is still controversially discussed
if this observation can be explained by the biological role
of the ALK-1 fusion proteins or by the younger age of the
Figure 1 Axial MRI of the left thigh delineates an ill-defining
tumor mass within the long head of the biceps femoris muscle
with vivid uptake of contrast media while measuring 4 × 3 × 9
cm in size.
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ALCL, which is characterized by t(2;5)(p23;q35) transloca-
tion and resulting in the expression of the NPM-ALK-1
fusion protein, so far no recurrent cytogenetic alterations
have been described in ALK-1 negative ALCL.
The presented case illustrates a CD30+, ALK-1+
ALCL of T-cell origin (CD2-/+, CD3+, CD7+, CD8+
and Perforin+) in a pediatric patient. Due to the abun-
dance of small neoplastic cells with pale cytoplasm
mixed with some medium-sized and large lymphoid
cells this case is best counted among the “small cell var-
iant” of ALCL (10%). Other ALCL subcategories are the
common (70-80%) and lymphohistiocytic type (10%).
Primary malignant lymphoma of soft tissue is an infre-
quent, and often diagnostically challenging neoplasm
[16,17]. Among those studies which reported the T- or
B-cell phenotype of primary soft tissue lymphoma, B-cell
accounted for over 90%. Most of those cases showed
aggressive histology and were of diffuse large B-cell phe-
notype [17]. T cell lymphomas in general and ALCL in
Figure 2 Histological features and immunophenotype of the intramuscular ALCL. (A) The biceps femoris muscle showed a tumoral and
diffuse polymorphic infiltration by large lymphoid cells (magnification 100×). Inlay: Majority of the cells were small to middle sized with
pleomorphic nuclei and various size of pale cytoplasm. Intermingled and less common larger cells with eccentric lobulated “horse shoe” or
“kidney-shape” nuclei and an abundant cytoplasm (so called “hallmark cells”) (magnification 400×). (B) Strong membranous and perinuclear dot-
like positivity for CD30 (magnification 100×). (C) T-cell phenotype of ALCL demonstrated by positivity for CD7 and CD8 (D) (magnification 100×).
(E) Tumor cells expressing ALK-1 protein both in the cytoplasm and nucleus indicating the classical t(2;5) translocation (magnification 200×). (F)
FISH with ALK Dual Color, Break Apart Rearrangement Probe for detecting translocations affecting 2p23 ALK breakpoint region. ALK locus in its
native state is seen as two immediately adjacent red and green signals. However, if a t(2;5) chromosome rearrangement has occurred as in this
case, one separate red and one separate green signals can be seen (the one remaining native ALK remains as an orange/green signal)
(magnification 1000×).
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of skeletal muscle [8-10]. Of note, all intramuscular pri-
mary ALCL cases reported so far have been ALK-1 posi-
tive. Why this T-cell lymphoma could overcome the
normally well established protection of skeletal muscle
against lymphocytic infiltration is unknown [18].
Interestingly, the current ALCL is the first among the
reported intra-muscular ALCL primaries to show a CD8
phenotype, which is extremely rare in ALCL. However,
trauma, which theoretically could have acted as a stimu-
latory trigger providing signals for T cell homing to ske-
letal muscle [18] was denied by the patient. Moreover,
no other infectious or autoimmune process was known
from the history or the local findings.
It should also be mentioned in this context that the
slightly enlarged lymph nodes were only detected after
MRI examination and were not clinically indicative.
Unfortunately a lymph node biopsy was not performed.
Therefore, a final statement about a possible secondary
involvement of the muscle was not possible. However, we
consider this possibility less likely because the majority of
ALCL patients (70%) presents with advanced stage III to
IV disease [3], which was obviously not the case in our
patient.
ALCL has to be distinguished from classical Hodgkin
lymphoma (cHL), CD30+ non-Hodgkin B cell lympho-
mas and very rare ALK-1 positive (and eventually CD30-
negative) large B cell lymphomas. Differential diagnosis
between ALCL and cHL can be made by expression of
cytotoxic molecules such as Granzyme B, Perforin and
T-cell-restricted intracellular antigen-1 (TIA1), EMA and
CD45/LCA which are typical of ALCL, while positivity
f o rC D 1 5( i n7 0 %o fc a s e s ) ,P A X 5( 9 0 % )a n dL M P 1( i n
50%) are typical of cHL. To distinguish ALCL from ALK-
1-positive large B cell lymphomas the lack of CD30
expression is critical and the t(2;5) translocation cannot
be demonstrated in the B cell lymphoma [19].
We conclude that this case represents a very rare mani-
festation of an ALCL in soft tissue. Despite the anaplastic
appearance a favorable outcome was possible after
promptly applying aggressive chemotherapy. The expres-
sion of the NMP-ALK-1 protein and the young age of the
patient might have influenced the positive outcome.
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